Buffer solution for tissue separation and preservation, application of buffer solution and method for culturing tumor organoids
By using specific combinations of buffers, including superoxide dismutase, catalase and other components, the problem of decreased cell activity during the isolation and transportation of liquid-derived tumor tissue samples was solved, and the success rate and number of tumor organoids were improved. , suitable for clinical testing and disease research.
Patent Information
- Application Number
- CN202411527774.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-30
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-10-30
AI Technical Summary
In the prior art, there are few reports of protective fluids used for the isolation of liquid-derived tumor tissue samples and long-term transportation of protective fluids, resulting in a decrease in tumor stem cell activity and a low success rate of tumor organoid construction.
Provide a buffer containing basal culture medium and specific additive factors, including superoxide dismutase, catalase, penicillin, streptomycin, vitamin E, transferrin, recombinant human albumin, Y27632, Gentamicin, amphotericin, N-acetylcysteine amide, etc. are used to preserve and transport tumor tissue samples to ensure the maintenance of tumor cell activity and function.
It significantly improves the retention rate of tumor cell activity and survival rate during transportation, increases the success rate and number of tumor organoids, and meets the needs of clinical testing and disease research.
Smart Images

Figure CN119020291A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of organoid culture, and in particular to a buffer for tissue separation and preservation and its application, and a method for culturing tumor organoids. Background Art
[0002] The transportation of liquid-derived tumor tissue samples is extremely important in biological experiments, and convenient and efficient in vitro storage and transportation methods are an indispensable part of it. Common liquid tumor samples include malignant effusion samples and peripheral blood samples. Malignant effusion is a physiological fluid that accumulates in the body of patients with malignant tumors. It is usually caused by the excessive accumulation of body fluids (serous fluid) when malignant tumor cells grow and spread in the body, invade surrounding tissues and organs, and destroy normal tissue structures. These malignant cells can be further spread through the blood circulation or lymphatic system, thereby accumulating in the cavities or organs of tumor patients. Malignant effusions mainly include malignant pleural effusions, malignant peritoneal effusions, malignant pericardial effusions, and malignant cerebral effusions. They are common pathophysiological phenomena of cancer. The fluids usually contain malignant tumor cells, proteins, cell fragments, white blood cells, red blood cells, extracellular fluids, and a variety of bioactive molecules. Their production and accumulation are closely related to the development and progression of tumors, and are crucial for the diagnosis and treatment of cancer. Circulating tumor cells (CTCs) are tumor cells that fall off from primary tumors or metastatic tumors and enter the blood circulation. The presence of CTCs in the blood is a sign that tumor cells have acquired invasiveness and metastasis. These cells evade the surveillance of the immune system through various mechanisms in the blood circulation and eventually colonize in distant tissues to form metastatic tumors. The presence and number of CTCs are closely related to the metastasis and recurrence of tumors. Therefore, the detection and monitoring of CTCs has become an important means to evaluate cancer progression and treatment efficacy.
[0003] Tumor organoids are a biological model that mainly uses the patient's tumor tissue for three-dimensional culture in vitro to simulate the biological characteristics of tumor tissue in vivo. Tumor organoids can simulate the microenvironment of tumor cell growth in vitro, which is of great significance for studying the occurrence, development, and drug response of tumors.
[0004] At present, there are few reports on protective solutions that can be used for the separation and long-term transportation of liquid-derived tumor tissue samples. The number of tumor organoids isolated and constructed from them is small, and the success rate is low. Therefore, the study of protective solutions suitable for the separation and transportation of liquid-derived tumor tissue samples is of great significance for ensuring the activity of tumor stem cells and improving the success rate and yield of tumor organoid construction. Summary of the invention
[0005] The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent. To this end, the present invention provides a buffer for tissue separation and / or preservation and its application. The buffer of the present invention is used for the transportation and protection of liquid-derived tumor tissue samples, and the tumor cell activity retention rate is high. The use of the buffer to construct tumor organoids has a high success rate and a large number, which can meet the needs of clinical detection and disease research.
[0006] In a first aspect of the present invention, the present invention provides a buffer. According to an embodiment of the present invention, the buffer is used to preserve a tumor tissue sample, the tumor tissue sample is of liquid origin; the buffer comprises: a basal culture medium and a specific additive factor, the specific additive factor comprises: superoxide dismutase, catalase, penicillin, and streptomycin.
[0007] According to an embodiment of the present invention, based on the volume of the basal culture medium, the concentration of the superoxide dismutase is 1-100 μg / mL, the concentration of the catalase is 50-500 μg / mL, the concentration of the penicillin is 50-200 U / mL, and the concentration of the streptomycin is 50-200 μg / mL.
[0008] Illustratively, the concentration of the superoxide dismutase can be 1 μg / mL, 10 μg / mL, 20 μg / mL, 30 μg / mL, 40 μg / mL, 50 μg / mL, 60 μg / mL, 70 μg / mL, 80 μg / mL, 90 μg / mL, or 100 μg / mL.
[0009] Illustratively, the concentration of the catalase can be 50 μg / mL, 100 μg / mL, 150 μg / mL, 200 μg / mL, 250 μg / mL, 300 μg / mL, 350 μg / mL, 400 μg / mL, 450 μg / mL, or 500 μg / mL.
[0010] Illustratively, the concentration of penicillin can be 50 U / mL, 75 U / mL, 100 U / mL, 125 U / mL, 150 U / mL, 175 U / mL, or 200 U / mL.
[0011] Illustratively, the concentration of streptomycin can be 50 μg / mL, 75 μg / mL, 100 μg / mL, 125 μg / mL, 150 μg / mL, 175 μg / mL, or 200 μg / mL.
[0012] The buffer according to the embodiment of the present invention is used for the separation, transportation and protection of liquid-derived tumor tissue samples, and has a high tumor cell activity retention rate. Tumor organoids can be constructed using the buffer with a high success rate and large quantity, which can meet the needs of clinical detection and disease research.
[0013] According to an embodiment of the present invention, based on the volume of the basal medium, the concentration of superoxide dismutase is 20 μg / mL, the concentration of catalase is 300 μg / mL, the concentration of penicillin is 100 U / mL, and the concentration of streptomycin is 100 μg / mL. Thus, the high activity of tumor cells during transportation and storage is further maintained.
[0014] According to an embodiment of the present invention, the specific additive factor further includes: vitamin E; based on the volume of the basal culture medium, the concentration of the vitamin E is 1.25 to 100 nM. The inventors have found through a large number of experiments that the three components of superoxide dismutase, catalase and vitamin E can synergistically enhance the activity of tumor cells and further improve the retention rate.
[0015] Exemplarily, the concentration of vitamin E can be 1.25 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM. According to an embodiment of the present invention, the specific additive factor also includes: transferrin, recombinant human albumin or human serum albumin, Y27632, gentamicin, and amphotericin.
[0016] According to an embodiment of the present invention, based on the volume of the basal culture medium, the concentration of the transferrin is 1 to 100 nM, the concentration of the recombinant human albumin or human serum albumin is 0.025 to 10 mg / mL, the concentration of the Y27632 is 0.5 to 50 μM, the concentration of the gentamicin is 1 to 100 μg / mL, and the concentration of the amphotericin is 10 to 1000 ng / mL.
[0017] Exemplarily, the concentration of transferrin can be 1 nM, 5 nM, 10 nM, 15 nM, 20 nM, 25 nM, 30 nM, 35 nM, 40 nM, 45 nM, 50 nM, 55 nM, 60 nM, 65 nM, 70 nM, 75 nM, 80 nM, 85 nM, 90 nM, 95 nM, 100 nM.
[0018] Exemplarily, the concentration of the recombinant human albumin or human serum albumin can be 0.025 mg / mL, 0.05 mg / mL, 0.1 mg / mL, 1 mg / mL, 2 mg / mL, 3 mg / mL, 4 mg / mL, 5 mg / mL, 6 mg / mL, 7 mg / mL, 8 mg / mL, 9 mg / mL, or 10 mg / mL.
[0019] Exemplarily, the concentration of Y27632 can be 0.5 μM, 1 μM, 10 μM, 15 μM, 20 μM, 25 μM, 30 μM, 35 μM, 40 μM, 45 μM, or 50 μM.
[0020] Illustratively, the concentration of gentamicin can be 1 μg / mL, 10 μg / mL, 20 μg / mL, 30 μg / mL, 40 μg / mL, 50 μg / mL, 60 μg / mL, 70 μg / mL, 80 μg / mL, 90 μg / mL, or 100 μg / mL.
[0021] Illustratively, the concentration of amphotericin can be 10 ng / mL, 50 ng / mL, 100 ng / mL, 200 ng / mL, 300 ng / mL, 400 ng / mL, 500 ng / mL, 600 ng / mL, 700 ng / mL, 800 ng / mL, 900 ng / mL, 1000 ng / mL.
[0022] The buffer according to the embodiment of the present invention can provide comprehensive protection and support for liquid-derived tumor tissue samples to improve cell survival rate and maintain cell function.
[0023] According to an embodiment of the present invention, based on the volume of the basal medium, the concentration of vitamin E is 25 nM, the concentration of transferrin is 20 nM, the concentration of recombinant human albumin or human serum albumin is 0.5 mg / mL, the concentration of Y27632 is 10 μM, the concentration of gentamicin is 10 μg / mL, and the concentration of amphotericin is 250 ng / mL. Thus, the high survival rate and high activity of tumor cells during transportation and storage are further maintained.
[0024] According to an embodiment of the present invention, the specific additive factor further comprises: N-acetylcysteine amide; based on the volume of the basal medium, the concentration of the N-acetylcysteine amide is 0.0625-10 mM, thereby further maintaining the survival and function of tumor cells and reducing cell death.
[0025] Illustratively, the concentration of N-acetylcysteine amide can be 0.0625 mM, 0.13 mM, 0.25 mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM.
[0026] According to an embodiment of the present invention, the concentration of N-acetylcysteine amide is 1.25 mM.
[0027] According to an embodiment of the present invention, the buffer solution further comprises 5 to 50 mM of a hydrogen ion buffer. Thus, the buffer solution according to an embodiment of the present invention can provide a more stable environment for a liquid-derived tumor tissue sample.
[0028] Illustratively, the concentration of the hydrogen ion buffer may be 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, or 50 mM.
[0029] According to an embodiment of the present invention, the hydrogen ion buffer is HEPES, and the concentration is 10 mM. Therefore, the buffer according to the embodiment of the present invention can further reduce the stress response of tumor cells during storage and transportation, reduce cell damage, and prolong the storage time.
[0030] According to an embodiment of the present invention, the basal medium is DMEM / F12. The inventors have found that the basal medium DMEM / F12 and the above-mentioned specific additive factors can work synergistically to provide a nutritionally suitable environment for a variety of tumor cells. Therefore, the buffer according to an embodiment of the present invention can be applied to a variety of tumor cells and help maintain their cell viability and function.
[0031] According to an embodiment of the present invention, the tumor tissue sample comes from at least one of malignant effusion, peripheral blood, bone marrow aspirate, alveolar lavage fluid, urine, and thoracic or abdominal puncture aspirate.
[0032] According to an embodiment of the present invention, the malignant effusion includes at least one of malignant pleural effusion, malignant peritoneal effusion, malignant pericardial effusion, and malignant hydrocephalus.
[0033] In this article, the term "malignant pleural effusion" refers to the accumulation of fluid in the pleural cavity caused by lung cancer, breast cancer, or other cancers that metastasize to the pleura. The term "malignant peritoneal effusion" is equivalent to "ascites" and is commonly seen in peritoneal effusions caused by ovarian cancer, gastric cancer, liver cancer, etc. The term "malignant pericardial effusion" refers to the accumulation of fluid in the pericardial cavity caused by certain cancers such as lung cancer and breast cancer that metastasize to the pericardium. The term "malignant cerebrospinal effusion" refers to the presence of tumor cells in the cerebrospinal fluid caused by brain tumors or cancer that metastasizes to the meninges. Tumor cells (circulating tumor cells, CTCs cells) are shed from the primary tumor or metastatic tumor and enter the blood circulation, so peripheral blood may contain tumor cells. In some cases, such as bone marrow fluid of patients with leukemia or certain types of lymphoma, tumor cells may be contained. In lung cancer or other lung diseases, fluid samples obtained by bronchoalveolar lavage through bronchoscopy may contain tumor cells. In some urinary system tumors (such as bladder cancer), tumor cells may be contained in the urine. Fluid drawn from the chest or abdominal cavity of a cancer patient may also contain tumor cells.
[0034] In a second aspect of the present invention, the present invention proposes the use of the aforementioned buffer in the preservation of tumor tissue samples, wherein the tumor tissue samples are of liquid origin.
[0035] Those skilled in the art will appreciate that the features and advantages described above for the buffer are also applicable to this application and will not be described in detail here.
[0036] According to an embodiment of the present invention, the tumor tissue sample comes from at least one of malignant effusion, peripheral blood, bone marrow aspirate, alveolar lavage fluid, urine, and thoracic or abdominal puncture aspirate.
[0037] According to an embodiment of the present invention, the malignant effusion includes at least one of malignant pleural effusion, malignant peritoneal effusion, malignant pericardial effusion, and malignant hydrocephalus.
[0038] According to an embodiment of the present invention, the tumor tissue sample is used for tumor organoid culture.
[0039] According to an embodiment of the present invention, the tumor organoids include: at least one of lung adenocarcinoma organoids, lung cancer organoids, breast cancer organoids, colorectal cancer organoids, ovarian cancer organoids, gastric cancer organoids, liver cancer organoids, brain tumor organoids, bladder cancer organoids, and meningeal cancer organoids.
[0040] In a third aspect of the present invention, a method for culturing tumor organoids is provided. According to an embodiment of the present invention, the method comprises: storing the tumor tissue sample in a buffer as described above before the organoid culture treatment, wherein the tumor tissue sample is of liquid origin. The method according to an embodiment of the present invention has a high success rate, a large number of samples, and good experimental repeatability.
[0041] Those skilled in the art will appreciate that the features and advantages described above for the buffer are also applicable to this method and will not be described in detail here.
[0042] According to an embodiment of the present invention, the tumor tissue sample comes from at least one of malignant effusion, peripheral blood, bone marrow aspirate, alveolar lavage fluid, urine, and thoracic or abdominal puncture aspirate.
[0043] According to an embodiment of the present invention, the malignant effusion includes at least one of pleural effusion, peritoneal effusion, pericardial effusion, and cerebrocerebral effusion.
[0044] According to an embodiment of the present invention, the tumor organoids include: at least one of lung adenocarcinoma organoids, lung cancer organoids, breast cancer organoids, colorectal cancer organoids, ovarian cancer organoids, gastric cancer organoids, liver cancer organoids, brain tumor organoids, bladder cancer organoids, and meningeal cancer organoids.
[0045] Compared with the prior art, the present invention has the following beneficial effects: 1. The tissue separation and / or preservation buffer of the present invention is suitable for short-term storage or transportation of primary liquid-derived tumor tissue samples and tissue separation, and can effectively avoid cell apoptosis, necrosis and the like during the separation, storage or transportation of samples, and maintain the biological function and vitality of tumor cells, especially tumor stem cells.
[0046] 2. The tissue separation and / or preservation buffer of the present invention can maintain the viability of most cells in liquid-derived tumor tissue samples for more than 48 hours at 4°C, significantly reducing the activity loss from sample separation to the start of the experiment, and effectively improving the success rate and organ quantity of tumor organoids constructed and cultured using various types of primary liquid tumor tissues.
[0047] 3. The tissue separation and / or preservation buffer of the present invention can also be used for resuspension and washing in the subsequent processing of tumor tissue samples.
[0048] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which: Figure 1Schematic diagram of the flow chart of separation and enrichment of tumor cells and culture of organoids in liquid-derived tumor tissue samples according to an embodiment of the present invention; wherein (A) is a schematic diagram of the flow chart of separation and enrichment of tumor cells and culture of organoids in malignant effusions; (B) is a schematic diagram of the flow chart of separation and enrichment of tumor cells and culture of organoids in peripheral blood samples; Figure 2 The optical microscope bright field images of lung adenocarcinoma organoids cultured from pleural effusion-derived tumor samples in the experimental group of Example 1 of the present invention, wherein (A) is the lung adenocarcinoma organoid on day 0 of culture; (B) is the lung adenocarcinoma organoid on day 3 of culture; (C) is the lung adenocarcinoma organoid on day 5 of culture; (D) is the lung adenocarcinoma organoid on day 7 of culture; (E) is the lung adenocarcinoma organoid on day 9 of culture; (F) is the lung adenocarcinoma organoid on day 12 of culture; scale bar: 100 μm; Figure 3 The optical microscope bright field images of lung adenocarcinoma organoids cultured from pleural effusion-derived tumor samples in the control group of Example 1 of the present invention, wherein (A) is the lung adenocarcinoma organoid on day 0 of culture; (B) is the lung adenocarcinoma organoid on day 3 of culture; (C) is the lung adenocarcinoma organoid on day 5 of culture; (D) is the lung adenocarcinoma organoid on day 7 of culture; (E) is the lung adenocarcinoma organoid on day 9 of culture; (F) is the lung adenocarcinoma organoid on day 12 of culture; scale bar: 100 μm; Figure 4 The immunohistochemical staining diagram of the lung adenocarcinoma organoids in the experimental group of Example 1 of the present invention, wherein (A) is the staining result of the immunohistochemical marker Ki67; (B) is the staining result of the immunohistochemical marker TTF-1; (C) is the staining result of the immunohistochemical marker Napsin A, and the scale bar is: 50 μm; Figure 5 The optical microscope bright field images of breast cancer organoids cultured from pleural effusion-derived tumor samples in Example 2 of the present invention, wherein (A) is the breast cancer organoid on day 0 of culture; (B) is the breast cancer organoid on day 3 of culture; (C) is the breast cancer organoid on day 6 of culture; (D) is the breast cancer organoid on day 10 of culture; (E) is the breast cancer organoid on day 14 of culture; (F) is the breast cancer organoid on day 17 of culture; scale bar: 100 μm; Figure 6 The immunohistochemical images of breast cancer organoids cultured from pleural effusion-derived tumor samples in Example 2 of the present invention, wherein (A) is the staining result of the immunohistochemical marker Ki67; (B) is the staining result of the immunohistochemical marker ER; (C) is the staining result of the immunohistochemical marker HER2; the scale bar is: 100 μm; Figure 7The optical microscope bright field images of colorectal cancer organoids cultured from peripheral blood-derived tumor samples in Example 3 of the present invention, wherein (A) is a colorectal cancer organoid on day 0 of culture; (B) is a colorectal cancer organoid on day 3 of culture; (C) is a colorectal cancer organoid on day 5 of culture; (D) is a colorectal cancer organoid on day 7 of culture; (E) is a colorectal cancer organoid on day 9 of culture; (F) is a colorectal cancer organoid on day 12 of culture; scale bar: 100 μm; Figure 8 The immunohistochemical images of colorectal cancer organoids cultured from peripheral blood-derived tumor samples in Example 3 of the present invention, wherein (A) is the staining result of the immunohistochemical marker Ki67; (B) is the staining result of the immunohistochemical marker CDX2; (C) is the staining result of the immunohistochemical marker CK20; the scale bar is: 100 μm. DETAILED DESCRIPTION
[0050] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.
[0051] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.
[0052] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0053] Terms and Definitions In order to make the present invention more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.
[0054] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention but not excluding other contents.
[0055] As used herein, the term "DMEM / F12" is a mixture of two culture media, Dulbecco's Modified Eagle's Medium (DMEM) and Ham's F-12 Medium, which are commercially available.
[0056] In some specific embodiments of the present invention, the formula of the buffer is as follows: based on the volume of the aforementioned basal culture medium, it contains 1 to 100 μg / mL of superoxide dismutase, 50 to 500 μg / mL of catalase, 50 to 200 U / mL of penicillin, and 50 to 200 μg / mL of streptomycin. The inventors have determined the basic components and concentrations of the buffer through a large number of experiments. The components at each concentration work synergistically to effectively protect tumor cells, reduce cell damage and death during separation, transportation and storage, and maintain high cell activity. Since the activity of tumor cells is effectively maintained, the liquid-derived tumor tissue samples separated or preserved using the buffer of the present invention have a significantly improved success rate when constructing tumor organoids, and the number of organoids obtained is significantly increased, which can meet the needs of clinical testing and disease research, and provide an important tool for the diagnosis, treatment and research of cancer.
[0057] In a specific embodiment of the present invention, the buffer solution is formulated as follows: based on the volume of the aforementioned basal culture medium, it comprises 20 μg / mL superoxide dismutase, 300 μg / mL catalase, 100 U / mL penicillin, 100 μg / mL streptomycin, 10 mM HEPES, and the remainder DMEM / F12 basal culture medium.
[0058] In some specific embodiments of the present invention, the formula of the buffer is as follows: based on the volume of the aforementioned basic culture medium, it comprises 1-100 μg / mL superoxide dismutase, 50-500 μg / mL catalase, 1.25-100 nM vitamin E, 50-200 U / mL penicillin, 50-200 μg / mL streptomycin, and the remainder is basic culture medium.
[0059] In a specific embodiment of the present invention, the buffer formula is as follows: based on the volume of the aforementioned basal culture medium, it comprises 20 μg / mL superoxide dismutase, 300 μg / mL catalase, 25 nM vitamin E, 100 U / mL penicillin, 100 μg / mL streptomycin, 10 mM HEPES, and the remainder DMEM / F12 basal culture medium.
[0060] In some specific embodiments of the present invention, the formula of the buffer is as follows: based on the volume of the aforementioned basal culture medium, it comprises 1-100 μg / mL superoxide dismutase, 50-500 μg / mL catalase, 1.25-100 nM vitamin E, 1-100 nM transferrin, 0.025-10 mg / mL recombinant human albumin or human serum albumin, 0.5-50 μM Y27632, 50-200 U / mL penicillin, 50-200 μg / mL streptomycin, 1-100 μg / mL gentamicin, 10-1000 ng / mL amphotericin, and the remainder of the basal culture medium.
[0061] In a specific embodiment of the present invention, the buffer formula is as follows: based on the volume of the aforementioned basal culture medium, it comprises 20 μg / mL superoxide dismutase, 300 μg / mL catalase, 25 nM vitamin E, 20 nM transferrin, 0.5 mg / mL recombinant human albumin, 10 μM Y27632, 100 U / mL penicillin, 100 μg / mL streptomycin, 10 μg / mL gentamicin, 250 ng / mL amphotericin, 10 mM HEPES, and the remainder DMEM / F12 basal culture medium.
[0062] In some specific embodiments of the present invention, the formula of the buffer is as follows: based on the volume of the aforementioned basal culture medium, it comprises 0.0625-10 mM N-acetylcysteine amide, 1-100 μg / mL superoxide dismutase, 50-500 μg / mL catalase, 1.25-100 nM vitamin E, 1-100 nM transferrin, 0.025-10 mg / mL recombinant human albumin or human serum albumin, 0.5-50 μM Y27632, 50-200 U / mL penicillin, 50-200 μg / mL streptomycin, 1-100 μg / mL gentamicin, 10-1000 ng / mL amphotericin, and the remainder of the basal culture medium.
[0063] In a specific embodiment of the present invention, the buffer formula is as follows: based on the volume of the aforementioned basal culture medium, it comprises 1.25 mM N-acetylcysteine amide, 20 μg / mL superoxide dismutase, 300 μg / mL catalase, 25 nM vitamin E, 20 nM transferrin, 0.5 mg / mL recombinant human albumin, 10 μM Y27632, 100 U / mL penicillin, 100 μg / mL streptomycin, 10 μg / mL gentamicin, 250 ng / mL amphotericin, 10 mM HEPES, and the remainder DMEM / F12 basal culture medium.
[0064] Each component of the buffer according to the embodiment of the present invention can work synergistically to adapt to the culture requirements of different types of cells within the above concentration range, further improve the success rate and quantity of constructing tumor organoids using liquid-derived tumor tissue samples, and improve the repeatability of the experiment. The N-acetylcysteine amide concentration of the aforementioned buffer can adapt to the antioxidant needs of different cell types within the above concentration range; the vitamin E concentration is within the above concentration range, which helps to fine-tune the redox balance in the cell; the transferrin concentration is within the above concentration range, which can ensure the effective supply of iron ions; recombinant human albumin or human serum albumin can provide necessary nutritional support for cells within the above concentration range; Y27632 is within the above concentration range, which helps to accurately control cell behavior and improve survival rate; gentamicin and amphotericin can provide effective antibacterial and fungal protection for cells within the above concentration range. Thus, according to the buffer according to the embodiment of the present invention, comprehensive protection and support can be provided for liquid-derived tumor tissue samples to improve cell survival rate and maintain cell function.
[0065] The inventors investigated the effects of different buffers on cell activity in liquid-derived tumor tissue samples. The investigation method and results are as follows: Buffer A formula: based on the volume of DMEM / F12 basal medium, 100 U / mL penicillin, 100 μg / mL streptomycin, 10 μM Y27632, 10 μg / mL gentamicin, 250 ng / mL amphotericin, and 10 mM HEPES; 20 μg / mL superoxide dismutase, 300 μg / mL catalase; the remainder is DMEM / F12 basal medium.
[0066] Buffer B formula: based on the volume of DMEM / F12 basal medium, 100 U / mL penicillin, 100 μg / mL streptomycin, 10 μM Y27632, 10 μg / mL gentamicin, 250 ng / mL amphotericin, and 10 mM HEPES; 20 μg / mL superoxide dismutase, 300 μg / mL catalase, 25 nM vitamin E; the remainder is DMEM / F12 basal medium.
[0067] Buffer C formula: based on the volume of DMEM / F12 basal medium, 100 U / mL penicillin, 100 μg / mL streptomycin, 10 μM Y27632, 10 μg / mL gentamicin, 250 ng / mL amphotericin, and 10 mM HEPES; 20 μg / mL superoxide dismutase, 300 μg / mL catalase, 25 nM vitamin E, 20 nM transferrin, and 0.5 mg / mL recombinant human albumin; the remainder is DMEM / F12 basal medium.
[0068] Buffer D formula: based on the volume of DMEM / F12 basal medium, 100 U / mL penicillin, 100 μg / mL streptomycin, 10 μM Y27632, 10 μg / mL gentamicin, 250 ng / mL amphotericin, and 10 mM HEPES; 1.25 mM N-acetylcysteine amide, 20 μg / mL superoxide dismutase, 300 μg / mL catalase, 25 nM vitamin E, 20 nM transferrin, and 0.5 mg / mL recombinant human albumin; the remainder is DMEM / F12 basal medium.
[0069] Buffer E formula: based on the volume of DMEM / F12 basal medium, 100 U / mL penicillin, 100 μg / mL streptomycin, 10 μM Y27632, 10 μg / mL gentamicin, 250 ng / mL amphotericin and 10 mM HEPES; the rest is DMEM / F12 basal medium.
[0070] Investigation method: The tumor tissue fluid of the same sample (colorectal cancer, lung adenocarcinoma tissue pleural effusion sample fluid) was divided into 5 parts, and placed in equal amounts of buffer A to buffer E respectively. After being stored at 4°C for 48 hours, it was centrifuged and washed, stained with trypan blue, and the cells were counted.
[0071] Investigation results: Trypan blue staining was used to observe and count the number and proportion of live cells in the two groups to determine the effects of different buffers on cell viability.
[0072] Table 1 Effects of different buffers on cell viability in liquid-derived tumor tissue samples
[0073] The results showed that buffers containing specific added factors such as superoxide dismutase, catalase, vitamin E, transferrin or recombinant human albumin can significantly improve the cell activity in liquid-derived tumor tissue samples. As a result, the survival rate and cell activity retention rate of tumor stem cells with self-proliferation ability in liquid-derived tumor tissue samples are further improved. Therefore, the success rate and number of organoids constructed using samples separated or preserved by the aforementioned buffer are further improved.
[0074] The scheme of the present invention will be explained below in conjunction with embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The main reagents used and their sources are shown in Table 2, and the reagents not included in Table 2 and the instruments not indicating the manufacturer are all conventional products that can be obtained by commercial purchase.
[0075] Table 2 Main reagent manufacturers and product numbers
[0076] Unless otherwise specified, in the embodiments of the present invention, the formulation and preparation method of the buffer for transporting liquid-derived tumor tissue samples are as follows: 1.25 mM N-acetylcysteine amide, 20 μg / mL superoxide dismutase, 300 μg / mL catalase, 25 nM vitamin E, 10 mM HEPES, 20 nM transferrin, 0.5 mg / mL recombinant human albumin, 10 μM Y27632, 10 μg / mL gentamicin, 250 ng / mL amphotericin, 100 U / mL penicillin, and 100 μg / mL streptomycin are added to Advanced DMEM / F12 culture medium.
[0077] Example 1: Preservation of pleural effusion-derived tumor tissue samples and construction of lung adenocarcinoma organoids refer to Figure 1 In this embodiment, the construction and culture of lung adenocarcinoma organoids derived from pleural effusion tumor tissue samples were performed according to the following experimental steps: (1) Pleural effusion samples from patients with lung adenocarcinoma were added to the pre-cooled tissue preservation solution of the present invention (experimental group) and the control group tissue preservation solution (Miltenyi tissue preservation solution, catalog number: abs9784-100mL), mixed and sent to the laboratory for pretreatment within 12 hours; (2) Centrifuge the effusion sample at 300 g for 5 min in a centrifuge, discard the supernatant, wash it with transport fluid, and centrifuge it again at 300 g for 5 min, and discard the supernatant; (3) Resuspend the pellet with 4 mL of 40% Percoll solution; (4) Add 4 mL of 70% Percoll solution to a 15 mL centrifuge tube, aspirate the 40% Percoll precipitate resuspension in step 3, and gently drop it onto the upper layer of the 70% Percoll solution to form a clear liquid surface boundary; aspirate the 20% Percoll solution and gently drop it onto the upper layer of the 40% Percoll solution to avoid mixing the two so that a clear liquid surface boundary is formed; (5) Perform density gradient centrifugation in a 15 mL centrifuge tube at 600 g for 20 min, with the centrifuge speed up 3 times and down 3 times. After centrifugation, aspirate the interface between the 20% Percoll solution and the 40% Percoll solution, add an appropriate amount of transport solution for cleaning, centrifuge at 300 g for 3 min, and discard the supernatant. (6) Take an appropriate amount of matrix gel to resuspend the cell pellet, and then use a pipette to inoculate the cell-mixed gel into a 24-well plate, with approximately 30 μL per well; (7) Take an appropriate amount of matrix gel and mix with the precipitate, inoculate into a 24-well plate, place the culture plate in a CO2 incubator and let it stand for 15-20 min. After it is fully solidified, add lung adenocarcinoma tumor organoid culture medium for culture. Observe the growth status of lung adenocarcinoma organoids under an inverted optical microscope ( Figure 2 , Figure 3 ); Lung adenocarcinoma organoids that were cultured for 7 days after three stable passages were taken for immunohistochemical staining ( Figure 4 ). In this example, immunohistochemical staining of three lung adenocarcinoma biomarkers, Ki67, TTF-1, and Napsin A, was performed to determine whether the obtained organoids had the characteristics of lung adenocarcinoma organoids.
[0078] In this embodiment, the culture conditions of lung adenocarcinoma organoids are as follows:
[0079] The results showed that: (1) compared with the control group, the success rate of lung adenocarcinoma organoids constructed and cultured using the tumor tissue liquid samples preserved and transported by the tissue preservation fluid of the present invention was significantly improved, the number of organoids was large, and the morphology was uniform; (2) the results of immunohistochemical staining showed that the lung adenocarcinoma biomarkers Ki67, TTF-1 and Napsin A were highly expressed in the lung adenocarcinoma organoids constructed and cultured using the tumor tissue liquid samples preserved and transported by the tissue preservation fluid of the present invention, and can be used for clinical detection and disease research of lung adenocarcinoma.
[0080] Example 2: Preservation of pleural effusion-derived tumor tissue samples and construction of breast cancer organoids refer to Figure 1 In this embodiment, the construction and culture of pleural effusion-breast cancer organoids were performed according to the following experimental steps: (1) Pleural effusion samples from breast cancer patients were added to the pre-cooled tissue preservation solution of the present invention (experimental group), mixed and sent to the laboratory for pretreatment within 12 hours; (2) Centrifuge the effusion sample at 300 g for 5 min in a centrifuge, discard the supernatant, wash it with transport fluid, and centrifuge it again at 300 g for 5 min, and discard the supernatant; (3) Resuspend the precipitate with 4 mL of 40% Percoll solution; (4) Add 4 mL of 70% Percoll solution to a 15 mL centrifuge tube, aspirate the 40% Percoll precipitate resuspension in step 3, and gently drop it onto the upper layer of the 70% Percoll solution to form a clear liquid surface boundary; aspirate the 20% Percoll solution and gently drop it onto the upper layer of the 40% Percoll solution to avoid mixing the two so that a clear liquid surface boundary is formed; (5) Perform density gradient centrifugation in a 15 mL centrifuge tube at 600 g for 20 min, with the centrifuge speed up 3 times and down 3 times. After centrifugation, aspirate the interface between the 20% Percoll solution and the 40% Percoll solution, add an appropriate amount of transport solution for cleaning, centrifuge at 300 g for 3 min, and discard the supernatant. (6) Take an appropriate amount of matrix gel to resuspend the cell pellet, and then use a pipette to inoculate the cell-mixed gel into a 24-well plate, with approximately 30 μL per well; (7) Take an appropriate amount of matrix gel and mix with the precipitate, inoculate into a 24-well plate, place the culture plate in a CO2 incubator and let it stand for 15-20 min. After it is fully solidified, add breast cancer tumor organoid culture medium for culture. Observe the growth status of breast cancer organoids under an inverted optical microscope. Figure 5 As shown; breast cancer organoids cultured for 7 days were subjected to immunohistochemical staining ( Figure 6 ). In this example, immunohistochemical staining of three breast cancer biomarkers, Ki67, ER, and HER2, was performed to determine whether the obtained organoids had the characteristics of breast cancer organoids.
[0081] In this embodiment, the culture conditions of breast cancer cell organoids are as follows:
[0082] The results showed that: (1) the success rate of breast cancer organoids constructed and cultured using the tumor tissue liquid samples preserved and transported by the tissue preservation fluid of the present invention was significantly improved, and the number of organoids was significantly increased; (2) the results of immunohistochemical staining showed that the breast cancer biomarkers Ki67, ER and HER2 were highly expressed in the breast cancer organoids constructed and cultured using the tumor tissue liquid samples preserved and transported by the tissue preservation fluid of the present invention, and could be used for clinical detection and disease research of breast cancer.
[0083] Example 3: Preservation of peripheral blood tumor tissue samples from patients with colorectal cancer and construction of colorectal cancer organoids refer to Figure 1 In this embodiment, the isolation of circulating tumor cells from colorectal cancer patients and the construction and culture of organoids were performed according to the following experimental steps: (1) Pre-cooled tissue preservation solution of the present invention (experimental group) was added to the peripheral blood samples of colorectal cancer patients and stored, and then sent to the laboratory for pretreatment within 12 hours; (2) Add an appropriate amount of Ficoll separation solution to the bottom of a new 15 mL centrifuge tube, tilt the centrifuge tube to a 30-45 degree angle, draw up the peripheral blood and CTCs mixture and slowly add it to the upper layer of the Ficoll separation solution.
[0084] (3) Transfer the centrifuge tube to a high-speed refrigerated centrifuge, set the acceleration to 9, the deceleration to 1, and centrifuge at 600 g for 30 min; (4) After gradient centrifugation, aspirate the second layer of milky white cell suspension from the bottom to the top and transfer it to a 15 mL centrifuge tube; (5) Add 3 mL-5 mL of transport solution to the centrifuge tube to resuspend the cells, adsorb the immune cells with Invitrogen Dynabeads CD45, collect the unadsorbed cell suspension in a 15 mL centrifuge tube, and centrifuge at low speed of 300 g for 3 min. (7) Take an appropriate amount of matrix gel to resuspend the cell pellet, and then use a pipette to inoculate the cell-mixed gel into a 24-well plate, with approximately 30 μL per well; (8) Take an appropriate amount of matrix gel and mix with the precipitate, inoculate into a 24-well plate, place the culture plate in a CO2 incubator and let it stand for 15-20 min. After it is fully solidified, add colorectal cancer organoid culture medium for culture. Observe the growth status of colorectal cancer organoids under an inverted optical microscope. Figure 7 As shown, colorectal cancer organoids cultured for 7 days were subjected to immunohistochemical staining ( Figure 8 ). In this example, immunohistochemical staining of three colorectal cancer biomarkers, Ki67, CDX2, and CK20, was performed to determine whether the obtained organoids had the characteristics of colorectal cancer organoids.
[0085] In this embodiment, the culture conditions of colorectal cancer cell organoids are as follows:
[0086] The results showed that: (1) the success rate of constructing and culturing colorectal cancer organoids using tumor tissue liquid samples preserved and transported using the tissue preservation fluid of the present invention was significantly improved, and the number of organoids was significantly increased; (2) the results of immunohistochemical staining showed that the colorectal cancer biomarkers Ki67, CDX2 and CK20 were highly expressed in the colorectal cancer organoids constructed and cultured using tumor tissue liquid samples preserved and transported using the tissue preservation fluid of the present invention, and can be used for clinical detection and disease research of colorectal cancer.
[0087] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A buffer for tissue separation and / or preservation, characterized in that The buffer is used to preserve tumor tissue samples, and the tumor tissue samples are of liquid origin; The buffer comprises: a basic culture medium and specific additive factors, wherein the specific additive factors comprise: superoxide dismutase, catalase, penicillin, and streptomycin; Based on the volume of the basic culture medium, the concentration of the superoxide dismutase is 1-100 μg / mL, the concentration of the catalase is 50-500 μg / mL, the concentration of the penicillin is 50-200 U / mL, and the concentration of the streptomycin is 50-200 μg / mL.
2. The buffer according to claim 1, characterized in that Based on the volume of the basal medium, the concentration of the superoxide dismutase was 20 μg / mL, the concentration of the catalase was 300 μg / mL, the concentration of the penicillin was 100 U / mL, and the concentration of the streptomycin was 100 μg / mL.
3. The buffer according to claim 1, characterized in that The specific additive factor also includes: vitamin E; based on the volume of the basic culture medium, the concentration of the vitamin E is 1.25-100 nM.
4. The buffer according to claim 3, characterized in that Based on the volume of the basal medium, the concentration of vitamin E is 25 nM.
5. The buffer according to claim 1, characterized in that The specific additive factors also include: transferrin, recombinant human albumin or human serum albumin, Y27632, gentamicin, and amphotericin; Based on the volume of the basal culture medium, the concentration of the transferrin is 1 to 100 nM, the concentration of the recombinant human albumin or human serum albumin is 0.025 to 10 mg / mL, the concentration of the Y27632 is 0.5 to 50 μM, the concentration of the gentamicin is 1 to 100 μg / mL, and the concentration of the amphotericin is 10 to 1000 ng / mL.
6. The buffer according to claim 5, characterized in that Based on the volume of the basal culture medium, the concentration of transferrin is 20 nM, the concentration of recombinant human albumin or human serum albumin is 0.5 mg / mL, the concentration of Y27632 is 10 μM, the concentration of gentamicin is 10 μg / mL, and the concentration of amphotericin is 250 ng / mL.
7. The buffer according to claim 5, characterized in that The specific additive factor also includes: N-acetylcysteine amide; based on the volume of the basic culture medium, the concentration of the N-acetylcysteine amide is 0.0625-10 mM.
8. The buffer according to claim 7, characterized in that The concentration of N-acetylcysteine amide was 1.25 mM.
9. The buffer according to any one of claims 1 to 8, characterized in that The buffer further includes 5-50 mM hydrogen ion buffer.
10. The buffer according to claim 9, characterized in that The hydrogen ion buffer is HEPES, and the concentration is 10 mM.
11. The buffer according to any one of claims 1 to 8, characterized in that The basic culture medium is DMEM / F12.
12. The buffer according to claim 1, characterized in that The tumor tissue sample is from at least one of malignant effusion, peripheral blood, bone marrow aspirate, bronchoalveolar lavage fluid, urine, and thoracic or abdominal puncture fluid.
13. Use of the buffer according to any one of claims 1 to 12 in the preservation of tumor tissue samples, wherein the tumor tissue samples are of liquid origin.
14. The use according to claim 13, characterized in that The tumor tissue sample is from at least one of malignant effusion, peripheral blood, bone marrow aspirate, bronchoalveolar lavage fluid, urine, and thoracic or abdominal puncture fluid.
15. The use according to claim 13, characterized in that: The tumor tissue sample is used for tumor organoid culture.
16. The use according to claim 15, characterized in that The tumor organoids include: at least one of lung adenocarcinoma organoids, lung cancer organoids, breast cancer organoids, colorectal cancer organoids, ovarian cancer organoids, gastric cancer organoids, liver cancer organoids, brain tumor organoids, bladder cancer organoids, and meningeal cancer organoids.
17. A method for culturing tumor organoids, characterized in that: include: Before the tumor tissue sample is subjected to the organoid culture treatment, it is stored in the buffer according to any one of claims 1 to 12, wherein the tumor tissue sample is of liquid origin.
18. The method according to claim 17, characterized in that The tumor tissue sample is from at least one of malignant effusion, peripheral blood, bone marrow aspirate, bronchoalveolar lavage fluid, urine, and thoracic or abdominal puncture fluid.
19. The method according to claim 17, characterized in that The tumor organoids include: at least one of lung adenocarcinoma organoids, lung cancer organoids, breast cancer organoids, colorectal cancer organoids, ovarian cancer organoids, gastric cancer organoids, liver cancer organoids, brain tumor organoids, bladder cancer organoids, and meningeal cancer organoids.
Citation Information
Patent Citations
Tumor tissue preserving fluid and application
CN112586495A
Body fluid tumor organoid culture method and drug sensitivity detection method
CN116751749A
Tissue preservation liquid for preservation and transportation of fresh tumor tissues and application of tissue preservation liquid
CN116998475A
Method for culturing colorectal cancer solid tumor primary cells and colorectal cancer ascites primary tumor cells and supporting reagents
US20210284970A1
